Evaluation of urinary excretion of dolutegravir or emtricitabine/tenofovir/elvitegravir/cobicistat antiretroviral-based regimens using plasma and urine trough concentration
Jérémy Lourenco,
Gilles Peytavin,
Véronique Avetttand-Fenoel,
Minh-Patrick Le,
Claire Rouzaud,
Fanny Lanternier,
Caroline Charlier-Woerther,
Fatima Touam,
Carole Louisin,
Olivier Lortholary,
Claudine Duvivier
Affiliations
Jérémy Lourenco
Necker Hospital, Infectious Diseases Department, Paris, France
Gilles Peytavin
Bichat-Claude Bernard Hospital, Pharmaco-Toxicology Department, Paris, France/Université Paris Diderot University, Sorbonne Paris Cité, IAME, INSERM UMR 1137, France
Véronique Avetttand-Fenoel
Necker-Enfants malades University Hospital, Clinical Microbiology Department, Paris, France
Minh-Patrick Le
Bichat-Claude Bernard Hospital, Pharmaco-Toxicology Department, Paris, France/Université Paris Diderot University, Sorbonne Paris Cité, IAME, INSERM UMR 1137, France
Claire Rouzaud
Necker Hospital, Infectious Diseases Department, Paris, France
Fanny Lanternier
Necker Hospital, Infectious Diseases Department, Paris, France
Caroline Charlier-Woerther
Necker Hospital, Infectious Diseases Department, Paris, France
Fatima Touam
Necker Hospital, Infectious Diseases Department, Paris, France
Carole Louisin
Necker Hospital, Infectious Diseases Department, Paris, France
Olivier Lortholary
Necker Hospital, Infectious Diseases Department, Paris, France
Claudine Duvivier
Necker Hospital, Infectious Diseases Department, Paris, France
